Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study)

Overview of attention for article published in BMC Ophthalmology, July 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 9,181 followers.

RT @mpwoodhead: New study to compare cost savings with Avastin vs Lucentis for AMS http://t.co/OO1bxAP91u Oz savings = $1.4b

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a ran… http://t.co/1odAUHIpyN

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a ran… http://t.co/1odAUHIpyN

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a ran… http://t.co/1odAUHIpyN

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.